JP4570246B2 - 細胞活性を調節する方法 - Google Patents

細胞活性を調節する方法 Download PDF

Info

Publication number
JP4570246B2
JP4570246B2 JP2000510431A JP2000510431A JP4570246B2 JP 4570246 B2 JP4570246 B2 JP 4570246B2 JP 2000510431 A JP2000510431 A JP 2000510431A JP 2000510431 A JP2000510431 A JP 2000510431A JP 4570246 B2 JP4570246 B2 JP 4570246B2
Authority
JP
Japan
Prior art keywords
sphingosine
sphingosine kinase
components
activity
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2000510431A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001515857A (ja
JP2001515857A5 (https=
Inventor
マシュー・バダス
ジェニファー・ギャンブル
プ・シア
フィリップ・バーター
ケリー−アン・ライ
ブライアン・ウォッテンバーグ
スチュアート・ピットソン
Original Assignee
ジョンソン アンド ジョンソン ファーマシューティカル リサーチ アンド デベロップメント エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジョンソン アンド ジョンソン ファーマシューティカル リサーチ アンド デベロップメント エルエルシー filed Critical ジョンソン アンド ジョンソン ファーマシューティカル リサーチ アンド デベロップメント エルエルシー
Publication of JP2001515857A publication Critical patent/JP2001515857A/ja
Publication of JP2001515857A5 publication Critical patent/JP2001515857A5/ja
Application granted granted Critical
Publication of JP4570246B2 publication Critical patent/JP4570246B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Food Science & Technology (AREA)
  • Vascular Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
JP2000510431A 1997-09-08 1998-09-08 細胞活性を調節する方法 Expired - Lifetime JP4570246B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU9002 1996-03-29
AUPO9002A AUPO900297A0 (en) 1997-09-08 1997-09-08 A method of modulating cellular activity
PCT/AU1998/000730 WO1999012533A1 (en) 1997-09-08 1998-09-08 A method of modulating cellular activity

Publications (3)

Publication Number Publication Date
JP2001515857A JP2001515857A (ja) 2001-09-25
JP2001515857A5 JP2001515857A5 (https=) 2006-01-05
JP4570246B2 true JP4570246B2 (ja) 2010-10-27

Family

ID=3803288

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000510431A Expired - Lifetime JP4570246B2 (ja) 1997-09-08 1998-09-08 細胞活性を調節する方法

Country Status (5)

Country Link
EP (1) EP1011654A4 (https=)
JP (1) JP4570246B2 (https=)
AU (2) AUPO900297A0 (https=)
CA (1) CA2302838C (https=)
WO (1) WO1999012533A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100798375B1 (ko) * 1999-05-13 2008-01-28 존슨 앤드 존슨 파머슈티컬 리서치 앤드 디벨로프먼트 엘엘씨 스핀고신 키나제 효소
AUPQ744700A0 (en) * 2000-05-11 2000-06-01 Medvet Science Pty. Ltd. A method of treatment and agents useful for same
EP1195604A1 (en) * 2000-09-29 2002-04-10 Warner-Lambert Company Methods and compositions for screening modulators of lipid kinases
US6610534B2 (en) * 2000-10-05 2003-08-26 Novartis Ag Induction of blood vessel formation through administration of polynucleotides encoding sphingosine kinases
US20050100547A1 (en) * 2001-06-07 2005-05-12 Pu Xia Etal Sphingosine kinase interacts with traf2 and modulates tumor necrosis factor-induced cellular activity
JP2005526809A (ja) * 2002-03-28 2005-09-08 メドベット サイエンス ピーティーワイ． リミティッド 細胞活性を調節する方法
MXPA05003974A (es) * 2002-10-14 2005-08-03 Medvet Science Pty Ltd Un metodo de modulacion de la actividad celular epitelial mediante la modulacion de los niveles funcionales de la esfingosina cinasa.
EP1481680A1 (en) * 2003-05-30 2004-12-01 Aventis Pharma Deutschland GmbH Use of S1P
EP1765384A4 (en) * 2004-06-15 2009-07-08 Medvet Science Pty Ltd METHOD FOR MODULATING CELLULAR ACTIVITY WITH SPHINGOSINE KINASE AND AGENTS THEREFOR, AND SPHINGOSINE KINASE VARIANTS
AU2005253643B2 (en) * 2004-06-15 2011-12-01 Medvet Science Pty. Ltd. Methods of modulating cellular activity involving sphingosine kinase and agents for same, and sphingosine kinase variants
EP1845971A4 (en) * 2005-01-21 2009-12-30 Medvet Science Pty Ltd METHOD FOR THE TREATMENT OF CELL DAMAGE
JP2013533286A (ja) 2010-07-30 2013-08-22 セントルイス ユニバーシティ 疼痛を治療する方法
WO2017015334A1 (en) 2015-07-21 2017-01-26 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766111A (en) * 1985-10-31 1988-08-23 Trustees Of Boston University Lipids with plasmin inhibitory properties
ATE133423T1 (de) * 1987-05-20 1996-02-15 Rogosin Inst Rekonstituierte hdl-teilchen und ihre verwendung
US5190876A (en) * 1988-12-27 1993-03-02 Emory University Method of modifying cellular differentiation and function and compositions therefor
CA2007507C (en) * 1989-02-03 1998-05-19 Yasuyuki Igarashi Sphingosine and n-methyl-sphingosine as inhibitor of cell growth
US5466716A (en) * 1990-12-31 1995-11-14 The Biomembrane Institute Liposomal trimethylsphingosine
CA2165982A1 (en) * 1993-07-23 1995-02-02 Fuqiang Ruan N,n,n-trimethylsphingosine derivatives
AU717243B2 (en) * 1994-12-29 2000-03-23 Regents Of The University Of California, The Compounds for inhibition of ceramide-mediated signal transduction
US5677189A (en) * 1995-06-29 1997-10-14 Oncomembrane, Inc. Method for quantifying sphingosine and for diagnosing platelet activation
JPH09176083A (ja) * 1995-12-28 1997-07-08 Sankyo Co Ltd 新規化合物ｆ−１２５０９ａ

Also Published As

Publication number Publication date
EP1011654A1 (en) 2000-06-28
EP1011654A4 (en) 2004-09-15
AU8965898A (en) 1999-03-29
CA2302838A1 (en) 1999-03-18
AU757358B2 (en) 2003-02-20
CA2302838C (en) 2010-03-16
JP2001515857A (ja) 2001-09-25
AUPO900297A0 (en) 1997-10-02
WO1999012533A1 (en) 1999-03-18

Similar Documents

Publication Publication Date Title
AU2003259803B2 (en) Diagnosis and treatment of tuberous sclerosis
Ragolia et al. Protein phosphatase-1 and insulin action
Moor et al. Protein kinase-mediated regulation of the Na+/H+ exchanger in the rat myocardium by mitogen-activated protein kinase-dependent pathways
US20080199896A1 (en) Diagnosis and Treatment of Diseases Arising from Defects in the Tuberous Sclerosis Pathway
Dodge et al. mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module
Pullamsetti et al. Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension
JP4570246B2 (ja) 細胞活性を調節する方法
Igarashi et al. Sphingosine 1-phosphate is a blood constituent released from activated platelets, possibly playing a variety of physiological and pathophysiological roles.
KR101390625B1 (ko) 티로신 키나제 억제제로의 처리시 세포 지방의 감소 및 심장 독성의 예측을 위한 조성물 및 방법
Ranek et al. Muscarinic 2 receptors modulate cardiac proteasome function in a protein kinase G-dependent manner
US7220539B1 (en) Protein kinase B/Akt modulators and methods for the use thereof
US20030134774A1 (en) Methods for inhibiting cardiac disorders
US20040018570A1 (en) Kinase inhibitors and methods of use in screening assays and modulation of cell proliferation and growth
US7364870B2 (en) MK2 interacting proteins
EP0887081A2 (en) Human serum glucocorticoid regulated kinase, a target for chronic renal disease
EP1272517B1 (en) Multiprotein-complexes comprising a nmda receptor and uses thereof
US20040213794A1 (en) Mst1 modulation of apoptosis in cardiac tissue and modultors of Mst1 for treatment and prevention of cardiac disease
Ward et al. TGFβ Regulates the Expression of Gαi2 via an Effect on the Localization of Ras
JP2007503203A (ja) インシュリン抵抗性の処置のための、ｓ６キナーゼ活性の阻害
AU2003204254B2 (en) A Method of Modulating Cellular Activity
US20070053910A1 (en) Modulation of s6 kinase activity for the treatment of obesity
US20080207671A1 (en) Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway
US20060234910A1 (en) Methods for the treatment of insulin resistance and disease states characterized by insulin resistance
WO2004035815A1 (en) Modulation of s6 kinase activity for the treatment of obestiy
El-Ani et al. Effects of theophylline and dibutyryl-cAMP on adenosine receptors and heart rate in cultured cardiocytes

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20040909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20040909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090302

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090805

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100713

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100810

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130820

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term